Pivotal data on finerenone might see it approved, but competing in the market will be trickier.
A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.
An attempt to abrogate the placebo response does not seem to have gone as planned.
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
A theoretical pivotal trial success fails to back omecamtiv’s commercial promise and leaves Amgen’s pipeline in dire straits.
Lilly’s doublet might be superior to Regeneron’s cocktail, but timing and manufacturing issues could now come into play.
The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.